Drug Patents owned by Chimerix

1. List of Tembexa drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9303051 CHIMERIX Phosphonate ester derivatives and methods of synthesis thereof
Aug, 2031

(8 years from now)

US8962829 CHIMERIX Morphic forms of hexadecyloxypropyl-phosphonate esters and methods of synthesis thereof
Oct, 2034

(11 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10112909 CHIMERIX Morphic forms of hexadecyloxypropyl-phosphonate esters and methods of synthesis thereof
Oct, 2034

(11 years from now)

US10487061 CHIMERIX Morphic forms of hexadecyloxypropyl-phosphonate esters and methods of synthesis thereof
Oct, 2034

(11 years from now)

US9371344 CHIMERIX Morphic forms of hexadecyloxypropyl-phosphonate esters and methods of synthesis thereof
Oct, 2034

(11 years from now)

Exclusivity Exclusivity Expiration
New Product (NP) Jun 4, 2024
Orphan Drug Exclusivity (ODE) Jun 4, 2028

Drugs and Companies using BRINCIDOFOVIR ingredient

Market Authorisation Date: 04 June, 2021

Treatment: Method of treating human smallpox disease

Dosage: SUSPENSION;ORAL

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in